Product
Help
Pricing
About
Jobs
Log in
Get started
Keyword
Add to collection
HER2 mutation
Description:
A genetic alteration in the HER2 gene, which encodes a receptor tyrosine kinase implicated in several cancers.
Primary topic:
Lung Cancer Treatments and Mutations (46%)
Related topics:
Lung Cancer Treatments and Mutations (46%),
HER2/EGFR in Cancer Research (30%)
OpenAlex ID:
keywords/her2-mutation
HER2-targeted therapies — a role beyond breast cancer
2019
·
Do-Youn Oh
, Yung-Jue Bang
·
Nature Reviews Clinical Oncology
·
1,173
The biology of erbB-2/nue/HER-2 and its role in cancer
1994
·
N Hynes
, D F Stern
·
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
·
1,149
Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)
2016
·
Fabrice Barlesi
, Julien Mazieres
, et al.
·
The Lancet
·
1,084
PDF
Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer
2012
·
Ron Bose
, Shyam M. Kavuri
, et al.
·
Cancer Discovery
·
947
Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low–Expressing Advanced Breast Cancer: Results From a Phase Ib Study
2020
·
Shanu Modi
, Haeseong Park
, et al.
·
Journal of Clinical Oncology
·
850
HER kinase inhibition in patients with HER2- and HER3-mutant cancers
2018
·
David M. Hyman
, Sarina A. Piha-Paul
, et al.
·
Nature
·
834
Somatic Mutations of the HER2 Kinase Domain in Lung Adenocarcinomas
2005
·
Hisayuki Shigematsu
, Takao Takahashi
, et al.
·
Cancer Research
·
742
Lung Cancer That Harbors an HER2 Mutation: Epidemiologic Characteristics and Therapeutic Perspectives
2013
·
Julien Mazières
, Solange Peters
, et al.
·
Journal of Clinical Oncology
·
730
Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer
2007
·
Tetsuya Mitsudomi
, Yasushi Yatabe
·
Cancer Science
·
649
Prevalence, Clinicopathologic Associations, and Molecular Spectrum of ERBB2 ( HER2 ) Tyrosine Kinase Mutations in Lung Adenocarcinomas
2012
·
Maria E. Arcila
, Jamie E. Chaft
, et al.
·
Clinical Cancer Research
·
560
Evolving concepts in HER2 evaluation in breast cancer: Heterogeneity, HER2-low carcinomas and beyond
2020
·
Caterina Marchiò
, Laura Annaratone
, et al.
·
Seminars in Cancer Biology
·
427
PDF
Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial
2020
·
Nicholas C Turner
, Belinda Kingston
, et al.
·
The Lancet Oncology
·
415
PDF
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study
2019
·
Kenji Tamura
, Junji Tsurutani
, et al.
·
The Lancet Oncology
·
380
Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer
2018
·
Funda Meric-Bernstam
, Amber M. Johnson
, et al.
·
Clinical Cancer Research
·
360
Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors
2015
·
M.G. Kris
, D.R. Camidge
, et al.
·
Annals of Oncology
·
351
A Comprehensive Review of HER2 in Cancer Biology and Therapeutics
2024
·
Xiaoqing Cheng
·
Genes
·
343
Genomic Characterization of Primary Invasive Lobular Breast Cancer
2016
·
Christine Desmedt
, Gabriele Zoppoli
, et al.
·
Journal of Clinical Oncology
·
340
Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort
2015
·
J. Mazières
, F. Barlesi
, et al.
·
Annals of Oncology
·
337
PDF
Efficacy and Safety of Anti–PD-1 Immunotherapy in Patients With Advanced NSCLC With BRAF, HER2, or MET Mutations or RET Translocation: GFPC 01-2018
2020
·
Florian Guisier
, Catherine Dubos-Arvis
, et al.
·
Journal of Thoracic Oncology
·
313
PDF
HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers
2020
·
Bob T. Li
, Flavia Michelini
, et al.
·
Cancer Discovery
·
311
HER2 Amplification and HER2 Mutation Are Distinct Molecular Targets in Lung Cancers
2015
·
Bob T. Li
, Dara S. Ross
, et al.
·
Journal of Thoracic Oncology
·
309
PDF
Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer
2018
·
S. Siena
, A. Sartore-Bianchi
, et al.
·
Annals of Oncology
·
263
PDF
Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor–directed therapies
2018
·
Utthara Nayar
, Ofir Cohen
, et al.
·
Nature Genetics
·
256
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study
2019
·
Kohei Shitara
, Hiroji Iwata
, et al.
·
The Lancet Oncology
·
245
Spectrum of Oncogenic Driver Mutations in Lung Adenocarcinomas from East Asian Never Smokers
2011
·
Chenguang Li
, Rong Fang
, et al.
·
PLoS ONE
·
245
PDF
Show more works
View as search
Works count:
1,245
Citation count:
29,000
Year
Topic
Type